Leadership

Dr. Sandberg serves as our Vice President of Regulatory and Compliance. She joined Pliant in October 2019.

Dr. Sandberg brings over 20 years of global strategic regulatory experience to Pliant with core drug development expertise in the areas of rare diseases and oncology. In her current role, Dr. Sandberg leads the regulatory and quality compliance functions with her tenure at Pliant having overseen the development and execution of the regulatory strategies and interactions involving our portfolio.  Prior to joining Pliant, Dr. Sandberg held roles of increasing responsibility over a 5-year period at Ultragenyx Pharmaceuticals, most recently serving as Senior Director of Regulatory Affairs, where she led the global regulatory strategies supportive of the commercialization of Crysvita^®, the first drug approved in XLH; a rare, inherited form of a softening and weakening of bones. Dr. Sandberg began her professional career at Amgen Inc. where she led the U.S. regulatory activities across multiple stages of development and therapeutics areas including oncology and inflammation.

Dr. Sandberg received her M.Sc. in Biomedical Chemistry from the University of Kalmar, Sweden, as well as a M.S. in Regulatory Science and a Ph.D. in Physiology and Biophysics from the University of Southern California.